<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03491995</url>
  </required_header>
  <id_info>
    <org_study_id>Helicobacter study</org_study_id>
    <nct_id>NCT03491995</nct_id>
  </id_info>
  <brief_title>A Unique Regimen for Treatment of Helicobacter Pylori Infection</brief_title>
  <official_title>A Unique Quadruple Regimen for of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The triple treatment including Proton pump inhibitor (PPI) -clarithromycin and amoxicillin or
      metronidazole was proposed 30 years ago at the first Maastricht conference to treat
      helicobacter pylori (H. pylori) infection and since that time, it has become the universal
      and standard treatment for helicobacter pylori.

      However, the efficacy of this triple regimen has been seriously challenged, and they are
      gradually becoming ineffective
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growing rates of treatment failure are observed worldwide and the eradication rate of triple
      therapy has declined over the past few decades. Helicobacter pylori infection has become
      increasingly resistant to traditional first line treatment regimens because of emerging
      antibiotic resistance coupled with poor patient compliance with completing the treatment
      course that decrease H. pylori eradication rates .So there is a considerable interest in
      evaluating new antibiotic combinations and regimens .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with eradicated Helicobacter infection</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with eradicated infection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Helicobacter Infections</condition>
  <arm_group>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Classic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omeprazole, clarithromycin, amoxicillin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadruple therapy</intervention_name>
    <description>Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin</description>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <other_name>Moxiflox, Downoprazol, Nanazoxid, Doxymycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Classic treatment</intervention_name>
    <description>Omeprazole, amoxycillin, clarithromycin</description>
    <arm_group_label>Classic treatment</arm_group_label>
    <other_name>Downoprazol, Emox, Klacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged older than 21 years Presenting by Dyspepsia Infected by H. pylori (as
             proved by positive stool antigen test) Agreed to participate in the study and signed
             the consent

        Exclusion Criteria:

          -  Patients who have received treatment with proton pump inhibitors within 2 weeks, NSAID
             or antibiotics within 4 weeks before study entry Patients who had received H pylori
             treatment before. Patients presenting by upper gastrointestinal bleeding Pregnant
             females Patients who have significant gastrointestinal, renal, hepatic,
             cardiovascular, metabolic, hematological disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman Yousry, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Hepatology and infectious diseases dept.-Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walied El-Hossary, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hepatology and infectious diseases dept.-Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Alboraie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Internal Medicine dept.-Alazhar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hepatology and Infectious diseases- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asem Elfert, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Hepatology and Infectious diseases- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hussein A Elamin, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Internal Medicine-Assuit University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Adel Elbasiony, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Internal Medicine- Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <phone>00201147773440</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-elsalam, lecturer</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2018</study_first_posted>
  <last_update_submitted>April 7, 2018</last_update_submitted>
  <last_update_submitted_qc>April 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

